MedTrace Logo

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

NCT02819882 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1867

Last updated 2026-04-07

No results posted yet for this study

Summary

This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.

Conditions

  • Breast Neoplasms

Interventions

OTHER

No intervention

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Director · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

  • Study Director · Hospital de Donostia, San Sebastián, Spain

  • Study Director · Hospital Universitario Gregorio Marañón, Madrid, Spain

  • Study Director · Instituto Valenciano de Oncología (IVO), Valencia, Spain

  • Study Director · Complejo Hospital Universitario A Coruña (CHUAC), Galicia, Spain

  • Study Director · Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819882 on ClinicalTrials.gov